Drugs & Targets FDA grants accelerated approval to avelumab for urothelial carcinoma May 12, 2017Vol.43 No.19
Drugs & Targets Novartis receives FDA approval for Kisqali Femara Co-Pack for initial treatment of HR+/HER2- advanced or metastatic breast cancer May 12, 2017Vol.43 No.19
Drugs & Targets European Commission approves dinutuximab beta for high-risk neuroblastoma May 12, 2017Vol.43 No.19
Drugs & Targets Reolysin gets FDA Fast Track designation for in metastatic breast cancer May 12, 2017Vol.43 No.19
Drugs & Targets PIQUR receives EMA Orphan Drug designation for PQR309 in diffuse large B-cell lymphoma May 12, 2017Vol.43 No.19
Drugs & Targets Addario Institute, Biocept collaborate on liquid biopsy trial in lung cancer May 12, 2017Vol.43 No.19
Drugs & Targets EpiThany, Merck KGaA, Pfizer to evaluate combination of avelumab and EP-101 STEMVAC in breast cancer May 12, 2017Vol.43 No.19
Drugs & Targets Array BioPharma, Merck collaborate to study MEK inhibitor with Keytruda May 12, 2017Vol.43 No.19
Drugs & Targets OncoSec, Merck to evaluate ImmunoPulse IL-12 and Keytruda in metastatic melanoma May 12, 2017Vol.43 No.19
Drugs & Targets Regeneron, SillaJen to test combination treatment in kidney cancer May 12, 2017Vol.43 No.19
